Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
07:30am, Friday, 22'nd May 2026
Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine, offering a differentiated risk-reward profile versus traditional biotech peers. ZYME's balance she
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
04:05pm, Thursday, 14'th May 2026
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipel
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Wednesday, 13'th May 2026
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipel
Zymeworks Q1 Earnings Call Highlights
05:07am, Saturday, 09'th May 2026
Zymeworks NASDAQ: ZYME reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
12:21am, Saturday, 09'th May 2026
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
08:11pm, Thursday, 07'th May 2026
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.3 per share a year ago.
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gas
Zymeworks (NASDAQ:ZYME) and ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Contrast
02:06am, Monday, 27'th Apr 2026
Zymeworks (NASDAQ: ZYME - Get Free Report) and ADVANZ PHARMA (OTCMKTS:CXRXF - Get Free Report) are both manufacturing companies, but which is the better business? We will contrast the two companies ba
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
03:12am, Sunday, 26'th Apr 2026
Zymeworks (NASDAQ: ZYME) used a presentation at the Bloom Burton conference to outline how the company is repositioning itself around its first approved product and a growing stream of royalty and mil
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of “Moderate Buy” from Analysts
04:24am, Thursday, 23'rd Apr 2026
Shares of Zymeworks Inc. (NASDAQ: ZYME - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat Ratings
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
05:30pm, Tuesday, 21'st Apr 2026
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip
Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable t
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
06:00am, Thursday, 16'th Apr 2026
VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
06:00am, Thursday, 09'th Apr 2026
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer
Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME
04:43am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd purchased a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange
